It has been debated, if the regulation of nAChR turnover by sympathetic innervation could explain the clear beneficial effects of sympathicomimetic treatments of patients suffering from several forms of congenital myasthenic syndromes (CMS) [169,186,187], a group of inherited neuromuscular disorders. The gene discussed is CHRNA4; the disease is congenital myasthenic syndrome.